|
Allergy Therapeutics PLC said on Thursday that the trial of its short-course peanut allergy vaccine candidate VLP Peanut has had ‘positive progress’ in phase 1 and phase 2a. The Sussex, England-based biotechnology company said the final stage of the PROTECT trial is ‘progressing as planned’. Allergy Therapeutics said that earlier interim analysis from the trial’s first two cohorts of peanut allergic patients indicated that ‘VLP Peanut is driving a reduction in allergic response to the major peanut allergen’. Allergy Therapeutics said ‘no relevant safety signals’ were identified across each of the trial’s cohorts, which were carried out on both healthy and peanut-allergic adult subjects. One final cohort of peanut allergic patients remains, with dosing expected to extend beyond the candidate’s anticipated therapeutic range. Chief Executive Officer Manuel Llobet said: ‘These results signal a major advance in the allergy research community’s search for what remains our holy grail - an effective short-course vaccine for people living with peanut allergy. ‘This vaccine candidate’s positive safety profile, together with encouraging early efficacy signals showing a strong immune response and reduced allergic reactivity, further strengthens our confidence in the programme and its potential to transform the lives of those affected by this most common and severe food allergy. ‘We look forward to progressing VLP Peanut, the most advanced peanut vaccine programme in the industry, into Phase 2b development and continuing to lead the way in allergy innovation.’ Shares in Allergy Therapeutics rose 3.8% in London on Thursday, closing at 8.30 pence. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
